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About 75% of all breast cancers are hormone receptor-positive (HR+). However, the
efficacy of endocrine therapy is limited due to the high rate of either pre-existing or
acquired resistance. In this work we reconstructed the pathways around estrogen
receptor (ER), mTOR, and cyclin D in order to compare the effects of CDK4/6
and PI3K/AKT/mTOR inhibitors. A positive feedback loop links mTOR and ER that
support each other. We subsequently considered whether a combined or sequential
inhibition of CDK4/6 and PI3K/AKT/mTOR could ensure better results. Studies indicate
that inhibition of CDK4/6 activates mTOR as an escape mechanism to ensure cell
proliferation. In literature, the little evidence dealing with this topic suggests that pre-
treatment with mTOR pathway inhibitors could prevent or delay the onset of CDK4/6
inhibitor resistance. Additional studies are needed in order to find biomarkers that can
identify patients who will develop this resistance and in whom the sensitivity to CDK4/6
inhibitors can be restored.
Keywords: breast cancer, estrogen receptor, cyclin-dependent kinases (CDKs), CDK inhibitors, mechanisms of
resistance
INTRODUCTION
Breast cancer presents a significant health burden worldwide according to the International
Agency for Research on Cancer1. About 75% of all breast cancers are hormone receptor-positive
(HR+). HR+ cancers express estrogen receptors (ER) and/or progesterone receptors (PgR). Such
tumors are basically dependent on the ER-related signaling pathway in order to grow and survive.
1http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
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The ER-related signaling pathway regulates various cellular
functions, such as apoptosis and cell proliferation as well as
angiogenesis. HR+ cancers take advantages of the ER pathway in
order to promote cancer development, growth, and progression
(Platet et al., 2004). This has led to the development of
therapeutic agents targeting the estrogen signaling pathway,
i.e., aromatase inhibitors (AIs; such as exemestane, anastrozole
and letrozole), selective down-regulators of ERs (fulvestrant),
selective modulators of ERs (tamoxifen). This endocrine therapy
has become the treatment of choice for breast cancers that are
HR+ (Milla-Santos et al., 2003; Di Leo et al., 2014).
The efficacy of such a therapeutic approach is however limited.
This, due to the high rate of pre-existing as well as acquired
resistance (Osborne and Schiff, 2011; De Marchi et al., 2016), has
led to a proportion of patients failing to respond to endocrine
therapy. Resistance to endocrine therapy is an important problem
from the clinical point of view.
Target Therapy: mTOR Inhibitors
Information on the PI3K/AKT/mTOR pathway has led to
the development of mTOR inhibitors (Hosford and Miller,
2014), including Everolimus. In 2012 this drug was approved
for the treatment of ER+/HER2- metastatic cancer following
progression on previous non-steroidal AI.
Effectiveness of combining endocrine therapy with mTOR
inhibitors has been tested in several trials, including the
TAMRAD trial, a randomized phase 2 trial of tamoxifen with
or without everolimus in postmenopausal women with AI-
resistant, ER+, advanced cancer. The combination arm was
associated with a significantly better progression-free survival
(PFS; 4.5 vs. 8.6 months) and overall survival (OS) (Bachelot
et al., 2012). BOLERO-2 is a phase 3 trial of exemestane
combined with either everolimus or placebo. This was conducted
in postmenopausal women with advanced ER+/HER2- cancer
resistant to either letrozole or anastrozole. The study showed
an improvement in PFS (3.2 months in the placebo/exemestane
arm vs. 7.8 months in the everolimus/exemestane arm)
(Yardley et al., 2013). Moreover, everolimus resulted to be
effective in combination with fulvestrant in AI-resistant luminal
metastatic cancer (NCT01797120) or with letrozole as first-line
treatment in postmenopausal patients with luminal metastatic
cancer (NCT01698918).
Target Therapy: CDK 4/6 Inhibitors
The advent of cyclin-dependent kinases (CDKs) 4/6 inhibitor-
based combination therapies represents a challenge for breast
cancer treatment. The development of inhibitors of CDK4 and
CDK6 has changed the perception of CDKs as therapeutic
targets in breast cancer following “underwhelming results and
unacceptable toxicity were seen with pan-CDK inhibitors such
as flavopiridol (alvocidib) in the early 2000s” (Fry et al.,
2004; Toogood et al., 2005; Hosford and Miller, 2014; Asghar
et al., 2015). Palbociclib is an orally active pyridopyrimidine,
highly selective reversible inhibitor of CDK4 and CDK6. The
effect of palbociclib is linked on the presence of a functional
retinoblastoma protein (Rb), whereas there is no effect on Rb-
deficient cells (Kim et al., 2014). On the other hand, abemaciclib,
and ribociclib are selective small molecule reversible inhibitors
of CDK4/6. It is hypothesized that the selectivity of palbociclib,
abemaciclib, and ribociclib is due to the specific interactions with
aminoacids of the ATP-binding site in the catalytic cleft of CDK4
and CDK6 (Asghar et al., 2015).
At present, no studies have directly compared the safety
and efficacy of the two sequences CDK4/6 inhibitor/everolimus
vs. everolimus/CDK4/6 inhibitor. Our computational study
aims to show the inhibition of the pathways by the CDK
4/6 inhibitors and everolimus and the biological rational of
sequencing or combining these two therapeutic strategies.
Literature search has been performed in PubMed by using
combinations of specific search terms, such as “breast,”
“resistance,” “CDK4,” “CDK6,” “mTOR,” “PI3K,” “inhibitor,”
or the corresponding drug names and their synonyms. We
have selected research articles from 2001 focusing on ER+
or triple negative cancer cell lines, human ER+ breast tumor
samples and patient derived xenograft models. Finally, some
review articles, analyzing alterations in the PI3K/AKT/mTOR
pathway in ER+ breast tumors associated with endocrine therapy
resistance, where selected.
CELL CYCLE SIGNALING PATHWAY
Cell cycle is regulated by the CDK4/6-Rb-E2F axis. Several other
factors strictly control this axis including cyclin D, INK4 family
proteins (p15INK4b, p16INK4a, p18INK4c, and p19INK4d), p21CIP1,
and p27Kip1 (Olmez et al., 2017).
The activated cyclin D-CDK4/6 complex provokes full
phosphorylation and functional inactivation of Rb. Rb active
form consists in its hypo-phosphorylated status. In this way,
active Rb acts as tumor suppressor primarily through binding
and consequent suppression of the nuclear E2F family of
transcription factors as well as by governing p27Kip1 stability
partly through interacting with APCCdh1; this causes cell
cycle arrest in the transition from G1 to S phase. Hyper-
phosphorylated Rb loses its suppressive role toward E2F in the
nucleus leading to the expression of E2F target genes required
for S-phase entry. In the cytoplasm, hyper-phosphorylated
Rb binds Sin1, a component of mTORC2 complex, thus
preventing AKT phosphorylation and mTORC1 activation
(Zhang et al., 2016; Bonelli et al., 2017; Figure 1). mTOR
signaling is activated by a variety of different signals such
as EGF, IGF-1, amino acids or high cellular energy. Growth
factors activate the phosphatidylinositol 3-kinase (PI3K) that
phosphorylates PIP2 to PIP3. The increased amount of PIP3
allows the co-localization of the serine/threonine kinase AKT,
phosphoinositide-dependent kinase-1 (PDK1) and mTORC2 to
the plasma membrane. PDK1 and mTORC2 phosphorylate
AKT leading to the complete AKT activation that, in turn,
activates mTORC1 (Kim et al., 2017). mTORC1 complex
(i) activates the transcription factor HIF1α that induces cell
growth and angiogenesis, (ii) releases the translation factor
eIF4E that enhances mRNA expression and export of genes
as cyclin D, therefore favoring cell proliferation (Rosenwald
et al., 1995; Michaloglou et al., 2018), (iii) activates the 40S
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FIGURE 1 | The ER, mTOR, and CDK4/6 pathways and their links are shown. Arrows indicate activation; arrows ending with oval tips indicate inhibition; P means
phosphorylation. It can be observed the presence of positive feedback loops that maintain the three pathways. In particular, mTOR pathway components sustain
estrogen pathway by activating ER independently of its ligands. Estrogen pathway sustains mTOR pathway by increasing the expression of its upstream receptors
and ligands. Additionally, estrogen and mTOR pathways reinforce CDK4/6 pathway through cyclin D expression. It should be noted that PI3K can also inhibit ER.
ER, estrogen receptor; PI3K, Phosphatidylinositol 3-kinase regulatory subunit alpha; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PIP2, phosphatidylinositol
(4,5)-bisphosphate; PTEN, phosphatase and tensin homolog; AKT, serine/threonine kinase 1; PDK1, pyruvate dehydrogenase kinase 1; mTOR, mammalian target of
rapamycin; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; mLST8, mammalian lethal with SEC13 protein 8, also known as G protein beta subunit-like
(GβL); Raptor, regulatory-associated protein of mTOR; PRAS40, Proline-rich AKT1 substrate 1; Deptor, DEP domain-containing mTOR-interacting protein; RICTOR,
Rapamycin-insensitive companion of mammalian target of rapamycin; SIN1, mammalian stress-activated protein kinase interacting protein 1; S6K1, ribosomal
protein S6 kinase B1; eIF4A, eukaryotic initiation factor-4A; HIFα, hypoxia inducible factor 1 subunit alpha; Rb, retinoblastoma protein; CDK4, cyclin dependent
kinase 4; CDK6, cyclin dependent kinase 6; E2F, transcription factor.
ribosomal S6 kinase 1 (S6K1) that increases protein synthesis
(Michaloglou et al., 2018).
Briefly, Rb is involved in two independent pathways. Hypo-
phosphorylated Rb suppresses E2F1, inducing the cell cycle
arrest at G1 phase. The hyper-phosphorylated Rb stops the
AKT oncogenic signaling pathways through mTORC2 inhibition
(Zhang et al., 2016).
Estrogens stimulate cell proliferation by increasing cyclin
D expression, but also in an indirect way through mTOR. In
fact, PI3K/AKT/mTOR cascade is also involved in ER pathway
triggering since S6K1, AKT, and PI3K induce ER phosphorylation
and activation independently to the estrogen presence (Campbell
et al., 2001; Yamnik et al., 2009). Consequently, despite the
estrogen deprivation, ER signaling can be activated resulting in
endocrine therapy resistance. The trigger of the ER signaling
pathway, both estrogen-dependent and independent, induces the
transcription of genes (such as IGF1-R, EGF, IRS-1, IGFBPs)
encoding for PI3K/AKT/mTOR pathway effectors resulting in a
positive feedback loop (Miller et al., 2011; Ciruelos Gil, 2014;
Figure 1). However, the interaction between these two pathways
seems more complicated, since there could be even an inverse
correlation of PI3K activation with ER expression levels. In
a model of ER+ cancer, PI3K inhibition led to an increase
of ER expression, whereas PI3K activation induced a decrease
of ER expression level (Creighton et al., 2010). This evidence
is supported by another study which demonstrated that in
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ER+ breast cancer models the PI3K inhibition enhanced the
expression of ER at both mRNA and at protein levels. This,
in turn, promoted the expression of the genes regulated by ER
(Bosch et al., 2015).
The combination of mTOR or PI3K inhibitors to CDK4/6
inhibitor therapy have shown encouraging preliminary results in
clinical trials, although PI3K inhibitors resulted to be quite toxic
and poorly effective and, therefore, they are not yet approved for
breast cancer (Hamilton and Infante, 2016; Cortes et al., 2017;
Ballinger et al., 2018).
Sequential Inhibition of CDK4/6 and
mTOR
The blockade of CDK4/6 activity by therapeutic inhibitors leads
to Rb de-phosphorylation and to the subsequent strengthening
of PI3K/AKT/mTOR pathway that plays a pivotal role in the
control of cell growth, migration and metabolism (Cretella et al.,
2018; Figure 2). mTORC2 inhibition lowers cell proliferation by
weakening of mTORC1, cyclin D, Rb axis. Additionally, ligand-
independent ER phosphorylation is reduced, leading to a lower
expression of growth factors and receptors and therefore to a
lower mTOR activation (Figure 3).
Recently, it has been showed that treatment with palbociclib
alone for 24 h in TNBC (triple negative breast cancer)
cell lines increases AKT activation. After palbociclib pre-
incubation, the sequential combined treatment with PI3K
inhibitors plus palbociclib was associated with G0/G1 cell
cycle arrest in a greater percentage of cells. This sequential
combined treatment determined a higher mTOR inhibition
and Rb de-phosphorylation, in comparison with the single or
simultaneous drug treatment. Notably, the sequential treatment
induced a stronger impairment of the glucose metabolism. In
fact, palbociclib treatment maintains Rb in its active form with
the consequent repression of E2F transcription factor and down-
regulation of the transcription factor c-myc, a direct target
of E2F. In turn, c-myc down-regulation results in decreased
expression of the GLUT-1 glucose transporter. The combination
of palbociclib with BYL719 (PI3K inhibitor) enhanced these
effects under normoxic and hypoxic conditions, since the
inhibition of PI3K/mTOR signaling is also involved in glucose
uptake decrease (Cretella et al., 2018).
The synergistic effect on cell cycle arrest and senescence of
sequential treatment with palbociclib and PI3K/mTOR inhibitors
was observed also in malignant pleural mesothelioma cell models
(Bonelli et al., 2017).
Combined Inhibition of CDK4/6 and
mTOR
ER+ breast cancer frequently shows a hyperactivation of the
mTOR pathway. Some studies have shown advantage from
combining mTOR inhibitors with estrogen receptor blockade
(Bachelot et al., 2012; Yardley et al., 2013). However, the precise
relationship among ER signaling and mTOR pathways has not
been clarified. Moreover, activation of CDK–Rb–E2F signaling
has often been associated with endocrine resistance; for this
reason, CDK4/6 inhibitors, such as palbociclib, are investigated
in clinical trials in ER+ cancer. In two breast cancer cell lines,
MCF-7 and ER+HCC-1428, the mTORC1/2 inhibitor vistusertib
(AZD2014) caused decreased levels of cyclin D1 resulting in
the hypo-phosphorylation of Rb, which in turn modulates
E2F mediated transcription. However, the combination with
palbociclib did not cause a complete growth inhibition and an
enhanced senescence-like phenotype, instead it resulted in a
prolonged quiescent state (Michaloglou et al., 2018).
In addition, a preclinical study assessing the effects of
palbociclib and the mTOR inhibitor sapanisertib, showed that
their combination synergistically inhibited breast cancer cell
proliferation (Yamamoto et al., 2019).
IMPLICATION FOR TREATMENTS IN
BREAST CANCER
The selection of systemic therapy in patients with advanced
cancers is mainly related to HR and HER2 status, previous
systemic therapies, and patient status. ER activity is effectively
inhibited by endocrine agents. In addition, estrogen/ER
complexes can also interact with AP-1 and SP-1 transcription
factors which are able to modulate different transcriptional
programs (Milla-Santos et al., 2003). On the other hand, the
non-nuclear mechanism of action of ER, which can be bound
to plasma membrane or free in the cytoplasm, consists in the
activation of RTKs (Receptor Tyrosine Kinases) family receptors
and, in turn, RTKs trigger their downstream pathways, such as
PI3K/AKT/mTOR and Ras/MAPK (Giuliano et al., 2013).
The approval of modern CDK inhibitors has changed
the treatment paradigm for advanced HR+ cancer. The use
of palbociclib, abemaciclib and ribociclib, that are selective
reversible inhibitors of CDK4 and CDK6, has been approved
based on progression free survival benefit seen on phase III
studies (Laderian and Fojo, 2017). Except for ER positivity, no
other biomarkers predictive of response to CDK4/6 inhibitors
have been identified so far.
Molecular Mechanism of Resistance to
CDK4/6 Inhibitors
Different molecular mechanisms of resistance to CDK4/6
inhibitors can arise (Pandey et al., 2019). They are due to p16,
CDK6, CCNE1/2, CDK2, CDK4, or E2F amplification and also
to loss of or mutations in Rb. It is remarkable that the loss of
Rb is responsible for activation of E2F and the cyclin E-CDK2
axis, assuring progression of the cell cycle. Recently, it was
elucidated that also loss of the FAT1 (FAT atypical cadherin 1)
tumor suppressor can promote resistance to CDK4/6 inhibitors
(Li et al., 2018). Therefore, there are different mechanisms of early
resistance to CDK4/6 inhibitors that favor alternative pathways of
S-phase entry.
CDK4/6 inhibitors or CDK4/6 inhibitor-resistant breast
cancer cells activate the PI3K/AKT/mTOR pathway (Herrera-
Abreu et al., 2016; Jansen et al., 2017; Pandey et al., 2019). mTOR
promotes cell proliferation and growth by suppressing autophagy
and promoting anabolic processes, such as biosynthesis of lipids
and proteins. mTOR could have a more complex role since
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FIGURE 2 | Dashed lines indicate a decreased interaction between two components or a diminished function. The effects of CDK4/6 inhibition are shown. Mainly,
Rb phosphorylation and its translocation into cytoplasm are prevented.
it also localizes in nucleus where it interacts with epigenetic
regulators. A recent study by Michaloglou et al. (2018) suggests
that, in CDK4/6 inhibitor-resistant ER-positive cancer cell
lines, inhibition of mTORC1/2 restores sensitivity to CDK4/6
inhibitors (Michaloglou et al., 2018). Another investigation shows
that PI3K inhibitors are able to prevent the resistance to CDK4/6
inhibitors. However, it fails to re-sensitize cells when resistance
is acquired (Herrera-Abreu et al., 2016). According to the above
mentioned in vitro studies, it seems better to hit mTOR first
in order to avoid or delay tolerance to CDK4/6 inhibitors.
Accordingly, in a small clinical trial including 23 metastatic
HR+/HER2- breast cancer patients treated with palbociclib after
pretreatment with everolimus, it has been reported a limited
clinical benefit, since poor response rate and short PFS have
been observed (Dhakal et al., 2018). Nevertheless, this data
should be confirmed in randomized clinical trials comparing
the sequences mTOR-CDK4/6 inhibitors vs. CDK4/6-mTOR
inhibitors in patients with breast cancer.
It is important to note that this pathway reconstruction could
have various limitations, including missing actors, unknown
interactions and particular cases, such as gene amplifications or
mutations that could cause the loss of function of some elements
not taken into account.
CDK4/6 Inhibitors in Combination With
Other Therapies
The use of CDK4/6 inhibitors is being investigated in
combination with other drugs, i.e., targeted therapy,
immunotherapy and chemotherapy.
Pre-clinical data suggest that there is a synergistic effect when
agents targeting the PI3K/mTOR pathway are combined with
CDK4/6 inhibition. Preliminary information on a few patients
has been observed when mTOR inhibitors (everolimus) and
α-specific PI3K inhibitor (alpelisib) are used with abemaciclib
and ribociclib. A phase Ib trial of ribociclib, everolimus,
and exemestane in 83 pre-treated patients with HR+/HER2-
advanced cancer showed an Overall Response Rate (ORR)
of 13%. Twenty-three percent of the patients had received
prior PI3K/AKT/mTOR inhibitors (Oliveira et al., 2016). The
combined therapy was basically well tolerated and the safety
profile was consistent with the combination of everolimus
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FIGURE 3 | The effects of mTOR inhibition are shown. It can be noted that mTOR inhibition causes cell proliferation arrest by cyclin D diminished synthesis and ER
target genes down-regulation.
and exemestane. Furthermore, abemaciclib was investigated
in combination with everolimus and exemestane in a small
number of patients with HR+/HER2- metastatic cancer. Of
the 15 patients that were evaluable for response assessment,
the ORR was 33%, the clinical benefit rate at 6 months being
73%. Recently, metastatic breast cancer patients treated with
the mTOR inhibitor everolimus, as first line therapy, have been
subsequently treated with fulvestrant and palbociclib, resulting
in a significantly better progression-free survival (Herrscher
et al., 2019). Currently, there are several ongoing trials exploring
combination of abemaciclib, ribociclib and palbociclib with
agents targeting the PI3K/mTOR pathway, including pan-PI3K
inhibitors (copanlisib), alpha-specific PI3K inhibitors (alpelisib,
GDC-0077), PI3K/mTOR dual inhibitor (LY3023414), and
mTOR inhibitors (everolimus).
It is reasonable to think that in some patients there is
the possibility to restore sensitivity to CDK4/6 inhibitors. This
could depend on which molecular mechanism is responsible for
the resistance. These studies need to be further developed; in
fact, they could reveal biomarkers to identify which patients
will develop resistance and which, among them, can recover
sensitivity to CDK4/6 inhibitors. Indeed, the identification of
patients who develop resistance to CDK4/6 inhibitors due to the
activation of PI3K/AKT/mTOR pathway will pave the way to
the combination of abemaciclib, ribociclib or palbociclib with
everolimus, alpelisib or copanlisib into daily clinical practice.
This will represent a major step forward on the road to precision
medicine in patients with advanced breast cancer.
CONCLUSION
The reconstruction of pathways around estrogen receptor (ER),
mTOR and cyclin D allowed the comparison of the effects
of CDK4/6 and PI3K/AKT/mTOR inhibitors in metastatic
HR+ cancer. Pre-treatment with mTOR pathway inhibitors
could prevent or delay the onset of resistance to CDK4/6
inhibitors. Additional studies are needed in order to find
the biomarkers that can identify patients who will develop
this resistance and in whom the sensitivity to CDK4/6
inhibitors can be restored. Moreover, the combination of
anti-mTOR/PI3K/AKT agents with CDK4/6 inhibitors should
be further investigated basing on the results obtained in
preliminary studies.
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